Form 4 for MGX Metagenomi Therapeutics, Inc.
Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-09 · accession 0001209191-24-003423 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-15 | 2024-02-09+ | MGX | Novo Holdings A/S | 10% | P - Purchase | $14.47 | +900.0K | 100.0K | New | +$13.03M |
| D | 2024-02-15 | 2024-02-13 | MGX | Novo Holdings A/S | 10% | C - Cnv Deriv | — | +839.2K | 939.2K | +839% | — |
| DM | 2024-02-15 | 2024-02-13 | MGX | Novo Holdings A/S | 10% | C - Cnv Deriv | — | -839.2K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2024-02-13 | P | A | 800,000 | $15.00 | 1,739,175 | D | — | — | (F2) Represents a purchase from the underwriters in the Issuer's initial public offering. |
| 2 | Common | COMMON STOCK | 2024-02-09 | P | A | 100,000 | $10.25 | 100,000 | D | — | — | |
| 3 | Common | COMMON STOCK | 2024-02-13 | C | A | 839,175 | — | 939,175 | D | — | — | (F1) Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. |
| 4 | Derivative | SERIES B PREFERRED STOCK | 2024-02-13 | C | D | 147,415 | — | 0 | D | — · — to — | 147,415 COMMON STOCK | (F1) Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. |
| 5 | Derivative | SERIES B-1 PREFERRED STOCK | 2024-02-13 | C | D | 691,760 | — | 0 | D | — · — to — | 691,760 COMMON STOCK | (F1) Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date. |